daclatasvir
Also known as BMS-790052, BMS 790052, BMS790052, Dimethyl N,N'-(biphenyl-4,4'-diylbis{1H-imidazole-5,2-diyl-((2S)-pyrrolidine-2,1- diyl)((1S)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)})dicarbamate, EBP 883, N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester, Daklinza
Daclatasvir, sold under the brand name Daklinza, is an antiviral medication used in combination with other medications to treat hepatitis C (HCV). The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. It is taken by mouth.
Key facts
- Drug.image
- Daclatasvir.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 275
- Drug.tradename
- Daklinza
- Drug.MedlinePlus
- a615044
- Drug.DailyMedID
- Daclatasvir
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AP07
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
~14 min read
Article
13 sectionsContents
- Medical use
- Adverse effects
- Interactions
- Pharmacology
- The role of NS5A in HCV replication
- Mechanism of action
- Pharmacokinetics
- History
- Synthesis
- Society and culture
- Economics
- Research
- References
{{Infobox drug | image = Daclatasvir.svg | image_class = skin-invert-image | width = 275 | alt = | caption =
| pronounce = | tradename = Daklinza | Drugs.com = | MedlinePlus = a615044 | DailyMedID = Daclatasvir | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = J05 | ATC_suffix = AP07